Acalisib | GS-9820 | CAL-120 | CAS#870281-34-8 | PI3K inhibitor MedKoo Biosciences

MedKoo Cat#: 205966 | Name: Acalisib

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Acalisib, also known as GS-9820, is an inhibitor of the beta and delta isoforms of the 110 kDa catalytic subunit of class IA phosphoinositide-3 kinases (PI3K) with potential immunomodulating and antineoplastic activities. p110beta/delta PI3K inhibitor GS-9820 inhibits the activity of PI3K, thereby preventing the production of the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3), which decreases tumor cell proliferation and induces cell death. PI3K-mediated signaling is often dysregulated in cancer cells; the targeted inhibition of PI3K is designed to preserve PI3K signaling in normal, non-neoplastic cells.

Chemical Structure

Acalisib

CAS#870281-34-8

Theoretical Analysis

MedKoo Cat#: 205966

Name: Acalisib

CAS#: 870281-34-8

Chemical Formula: C21H16FN7O

Exact Mass: 401.1400

Molecular Weight: 401.40

Elemental Analysis: C, 62.84; H, 4.02; F, 4.73; N, 24.43; O, 3.99

Price and Availability

Size	Price	Availability
10mg	USD 115.00	Ready to ship
25mg	USD 230.00	Ready to ship
50mg	USD 385.00	Ready to ship
100mg	USD 650.00	Ready to ship
200mg	USD 1,150.00	Ready to ship
500mg	USD 2,450.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

GS-9820; GS9820; GS 9820; CAL120; CAL 120; CAL-120; Acalisib.

IUPAC/Chemical Name

(S)-2-(1-((7H-purin-6-yl)amino)ethyl)-6-fluoro-3-phenylquinazolin-4(3H)-one.

InChi Key

DOCINCLJNAXZQF-LBPRGKRZSA-N

InChi Code

InChI=1S/C21H16FN7O/c1-12(27-19-17-18(24-10-23-17)25-11-26-19)20-28-16-8-7-13(22)9-15(16)21(30)29(20)14-5-3-2-4-6-14/h2-12H,1H3,(H2,23,24,25,26,27)/t12-/m0/s1

SMILES Code

O=C1N(C2=CC=CC=C2)C([C@@H](NC3=C4NC=NC4=NC=N3)C)=NC5=C1C=C(F)C=C5

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#C9R07B23

QC Data

View QC data: current batch, Lot#C9R07B23

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

Acalisib (GS-9820, CAL-120) is a highly selective and potent p110δ inhibitor (IC50 = 14 nM) with 114- to 400-fold selectivity over the other class I PI3K enzymes and no activity against Class II and III PI3K family members or other PI3K-related proteins including mTOR and DNA-PK.

In vitro activity:

The novel PI3Kδ inhibitor GS-9820 (Acalisib) (Table 2A) was characterized using in vitro activity assays. It was found that GS-9820 was more selective for PI3Kδ relative to other PI3K class I enzymes (IC50: PI3Kα, 5,441 nm; PI3Kβ, 3,377 nm; PI3Kγ, 1,389 nm; and PI3Kδ, 12.7 nm) (Table 2B). GS-9820 was also 103-fold more selective against PI3Kδ than against related kinases, such as CIIβ, hVPS34, DNAPK, and mammalian target of rapamycin. EC50 values were characterized using in vitro cell-based assays. GS-9820 reduced PDGF-induced pAkt by only 50% at 11,585 nm, and LPA-induced pAkt by 50% at 2,069 nm (Table 2C). Expression of PI3Kγ and PI3Kδ is largely restricted to cells of hematopoietic origin, including basophils. GS-9820 suppressed FcϵRI PI3Kδ-mediated CD63 expression with an EC50 of 14 nm, and fMLP PI3Kγ-mediated CD63 expression with an EC50 of 2,065 nm (supplemental Fig. S2). Thus, GS-9820 showed selectivity for PI3Kδ over the other class I PI3K isoforms and virtually no binding to a panel of other kinases. Reference: J Biol Chem. 2013 Dec 6;288(49):35346-57. https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24133210/

In vivo activity:

To dissect the relative contribution of PI3Kɑ inhibition in the reduction of obesity, obese hyperphagic ob/ob mice were treated with a selective PI3Kδ inhibitor, GS-9820 (Acalisib). GS-9820 had no significant effect on body weight (Figure 1A and and 1B). It should be noted that 10 mg/kg of GS-9820 is sufficient to reduce the growth of multiple myeloma xenografts in mice. Obese ob/ob mice are insulin resistant and therefore their glycemic excursions were severe (up to 500 mg/dl) in the case of the two PI3Kɑ inhibitors, CNIO-PI3Ki and BYL-719, whereas GS-9820 had a comparatively minor effect (Figure 2A). GS-9820 had no detectable effect on serum lipids. Refernece: Aging (Albany NY). 2016 Nov 4;8(11):2747-2753. https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/27816049/

	Solvent	mg/mL	mM
Solubility
	DMSO	80.0	199.30

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 401.40 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

In vitro protocol:

1. Shugg RP, Thomson A, Tanabe N, Kashishian A, Steiner BH, Puri KD, Pereverzev A, Lannutti BJ, Jirik FR, Dixon SJ, Sims SM. Effects of isoform-selective phosphatidylinositol 3-kinase inhibitors on osteoclasts: actions on cytoskeletal organization, survival, and resorption. J Biol Chem. 2013 Dec 6;288(49):35346-57. doi: 10.1074/jbc.M113.507525. Epub 2013 Oct 16. PMID: 24133210; PMCID: PMC3853283.

In vivo protocol:

1. Lopez-Guadamillas E, Muñoz-Martin M, Martinez S, Pastor J, Fernandez-Marcos PJ, Serrano M. PI3Kα inhibition reduces obesity in mice. Aging (Albany NY). 2016 Nov 4;8(11):2747-2753. doi: 10.18632/aging.101075. PMID: 27816049; PMCID: PMC5191867.

1: Kater AP, Tonino SH, Spiering M, Chamuleau MED, Liu R, Adewoye AH, Gao J, Dreiling L, Xin Y, Doorduijn JK, Kersten MJ; HOVON Lunenburg Lymphoma Phase I/II Consortium. Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies. Blood Cancer J. 2018 Feb 12;8(2):16. doi: 10.1038/s41408-018-0055-x. PMID: 29434192; PMCID: PMC5809482. 2: Lopez-Guadamillas E, Muñoz-Martin M, Martinez S, Pastor J, Fernandez-Marcos PJ, Serrano M. PI3Kα inhibition reduces obesity in mice. Aging (Albany NY). 2016 Nov 4;8(11):2747-2753. doi: 10.18632/aging.101075. PMID: 27816049; PMCID: PMC5191867.